Additional studies will be necessary to identify underlying disease mechanisms responsible for activation of specific pathways within AAT-expressing cells as well as heterogeneity that could exist within the ZZ-AATD population. The gene discussed is SERPINA1; the disease is alpha 1-antitrypsin deficiency.